AtaGenix, China  

Founded in Wuhan in 2011, AtaGenix Laboratories operates as an R&D and production partner for the research community. The company has established a suite of proprietary technologies that include high-density mammalian cell expression systems, MHC–peptide complex expression, multimer-directed expression platforms, hybridoma-based mouse monoclonal antibody production, single B-cell antibody discovery, stable cell line generation for large-scale manufacturing, phage library construction and screening, and advanced antibody engineering capabilities encompassing humanization, affinity maturation, and bispecific antibody development.